Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions (Q36349758)

13 August 2017

1 reference

title

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions (English)

1 reference

13 August 2017

1 reference

1 reference

Michael H Davidson

1

1 reference

PubMed ID

16370963

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Drug Safety

13 August 2017

1 reference

13 August 2017

5

1 reference

13 August 2017

145-156

1 reference

13 August 2017

1

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Antiatherogenic properties of fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Controversy surrounding the safety of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Combination therapy for dyslipidemia: safety and regulatory considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Interaction between fibrates and statins--metabolic interactions with gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Simvastatin, fenofibrate, and rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Risk of adverse events with fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.145

21 January 2018

Identifiers

DOI

10.1517/14740338.5.1.145

1 reference

13 August 2017

1 reference

PubMed ID

16370963